How many clinical trials are tracked for Endometriosis?

46 trials are tracked, 12 with published results.

Endometriosis Research

Endometriosis: what the trials found

Several GnRH antagonists and agonists have been evaluated for the management of endometriosis-related pain. Elagolix demonstrated significant improvements in both dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP) at 3 months compared to placebo, with statistically significant reductions in Numeric Rating Scale (NRS) scores [14, 15, 19, 20]. Linzagolix showed a significant proportion of responders for dysmenorrhea at month 3 ¹⁷, while relugolix demonstrated high responder rates for both DYS and NMPP at weeks 52 and 104 ¹⁶.

Hormonal treatments including estradiol/norethindrone acetate showed statistically significant improvements in DYS and NMPP outcomes at months 6 and 12 ¹⁸. Triptorelin pamoate was shown to effectively achieve castrated status (E2 levels ≤184 Pmol/L or 50 pg/mL) by week 12 ²¹.

Cyclic microgestin 1/20 showed a statistically significant reduction in bladder pain sensitivity from baseline, though changes in pelvic hyperalgesia and cortical activity were not significantly different from baseline ¹⁰. Ulipristal was associated with a statistically significant reduction in pelvic pain ¹¹.

For the clinician treating this condition

Elagolix, linzagolix, and relugolix are established options for reducing both dysmenorrhea and non-menstrual pelvic pain.
Estradiol/norethindrone acetate and triptorelin pamoate provide established pathways for managing symptoms or achieving hormonal castration status.
Cyclic microgestin 1/20 is associated with reduced bladder pain sensitivity, though its impact on hyperalgesia parameters is not statistically confirmed.

AI synthesis of 11 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.